辛伐他汀与左卡尼丁联合治疗高脂血症的疗效分析

目的:探讨辛伐他丁与左卡尼丁联合治疗混合性高脂血症的临床疗效及安全性.方法:100例混合性高脂血症患者,随机分为辛伐他丁组(n=33,20 mg/d)、左卡尼丁组(n=32,3 g/d)和联合治疗组(n=35,辛伐他丁20 mg/d和左卡尼丁3 g/d),疗程均为4个月.观察治疗前后血脂指标的变化、达标率以及不良反应.结果:联合治疗组血脂变化最显著,血清总胆同醇(TC),低密度脂蛋白(LDL-C)和甘油三酯(TG)均下降,而血清高密度脂蛋白胆固醇(HDL-C)升高(P均<0.01).联合治疗组TC、LDL-C、TG的达标率分别为51.4%、48.6%、57.1%,三项指标全部达标者为46.7%,明显高于单药治疗组(P<0.01).联合治疗组不良反应发生率和单药治疗组相比差异无统计学意义(P均>0.05).结论:辛伐他丁与左卡尼丁联合可以更全面地改善混合性高脂血症,较单药治疗更为有效,具有良好的安全性和耐受性.     

六味能消胶囊联合非诺贝特和辛伐他汀治疗混合性高脂血症的疗效观察

目的观察六味能消胶囊联合非诺贝特和辛伐他汀治疗混合性高脂血症的临床疗效。方法选取2015年7月—2016年6月在澄迈县人民医院就诊的混合性高脂血症患者106例,随机分为对照组和治疗组,每组各53例。对照组口服非诺贝特胶囊,200 mg/次,1次/d;同时晚睡前口服辛伐他汀片,20 mg/次,1次/d。治疗组在对照组的基础上口服六味能消胶囊,1粒/次,3次/d。两组均连续治疗8周。比较两组治疗前后临床疗效和血脂水平。结果治疗后,对照组和治疗组的总有效率分别为79.24%、90.57%,两组总有效率比较差异有统计学意义(P0.05)。治疗后,两组患者三酰甘油(TG)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)水平显著下降,高密度脂蛋白胆固醇(HDL-C)水平明显升高,同组治疗前后差异具有统计学意义(P0.05);且治疗组上述血脂指标水平改善优于对照组,两组比较差异具有统计学意义(P0.05)。结论六味能消胶囊联合非诺贝特和辛伐他汀治疗混合性高脂血症临床疗效确切,可显著降低血脂水平,具有一定的临床推广应用价值。     

辛伐他汀联合非诺贝特治疗混合性高脂血症的疗效观察及注意事项

目的探讨辛伐他汀联合非诺贝特治疗混合性高脂血症的可行性及注意事项。方法混合性高脂血症210例患者随机分为辛伐他汀组、非诺贝特组、联合用药组各70例;辛伐他汀组每晚口服辛伐他汀20mg、非诺贝特组每晚服非诺贝特200mg、联合用药每日清晨口服非诺贝特200mg,晚口服辛伐他汀10mg,用药均为12周。结果辛伐他汀组治疗后TC、LDL-C显著性下降,TG、HDL-C变化不明显;非诺贝特组治疗后TG显著性下降,HDL-C升高,TC、LDL-C变化不明显;联合用药组TC、LDL-C、TG均有显著性下降,HDL-C升高。联合用药组总有效率总有效率78.5%高于辛伐他汀组的64.3%、非诺贝特组的61.4%。3组血清CK、肝肾功能等检查均无明显变化,未出现肌病症状及退出或终止病例。结论辛伐他汀联合非诺贝特治疗混合性高脂血症具有临床可行性,但应该注意掌握适应症、服药方法、取得患者的知情同意、定期监测。     

氟伐他汀联合非诺贝特治疗混合性高脂血症疗效观察

目的探讨小剂量氟伐他汀与非诺贝特联合应用治疗混合型高血脂症的临床疗效及安全性。方法混合型高血脂症患者182例,随机分为3组,即氟伐他汀组（40mg/d,n=60）、非诺贝特组（200mg/d,n=58）、联合治疗组（氟伐他汀40mg/d＋非诺贝特200mg/d,n=64）,治疗12周;观察治疗前后主要血脂水平的达标率及不良反应。结果12周时联合治疗组血清总胆固醇（TC）、低密度脂蛋白胆固醇LDL-C、三酰甘油（TG）下降的幅度均高于单独用药组（P〈0.05）;TC、LDL-C、TG3项全部达标率也高于单独用药组（P〈0.05）。联合治疗的不良反应与单独用药相比无明显增加。结论小剂量氟伐他汀（40mg/d）与非诺贝特（200mg/d）联合治疗混合型高血脂症,较单独用药更有效、更全面地改善各项血脂水平,具有良好的安全性和耐受性。     

血脂康治疗2型糖尿病合并高脂血症的临床观察

目的:观察血脂康对2型糖尿病合并高脂血症患者的调脂作用.方法:92例2型糖尿病合并高脂血症的患者分为血脂康组32例及其他降脂药对照组60例(普伐他汀组30例、非诺贝特组30例).分别选用血脂康1.2 g·d-1、普伐他汀20 mg·d-1、非诺贝特0.2 g·d-1.疗程8周,比较治疗前后血脂的变化.结果:血脂康组治疗后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)分别下降33.8%、35.3%、35.9%,治疗前后比较差异有极显著性(P＜0.01),TC下降较非诺贝特组更明显(P＜0.01),治疗后LDL-C的下降和高密度脂蛋白胆固醇(HDL-C)的升高的疗效与普伐他汀组等同(P＞0.05).结论:血脂康是一种安全、有效、调脂作用良好的药物;还具有抗动脉粥样硬化的作用.     

辛伐他汀联合非诺贝特治疗高脂血症50例疗效评价

目的 探讨辛伐他汀联合非诺贝特治疗高脂血症的疗效及安全性,为临床高脂血症的治疗提供用药参考。方法 选取2011年1月至2014年1月收治的100例高脂血症患者,随机分为两组。A组(50例)睡前服用辛伐他汀10 mg,B组(50例)在此基础上于早、午各口服非诺贝特100 mg。连续治疗8周后比较两组患者调脂效果和不良反应。结果 两组患者治疗8周后,血脂水平均有改善,但B组的总胆固醇(TC)、三酰甘油(TG)水平均明显低于A组,血清高密度脂蛋白胆固醇(HDL-C)水平均明显高于A组(P<0.05);B组的降TC有效率及升HDL-C有效率均高于A组,但不良反应发生率与A组比较,差异无统计学意义(P>0.05)。结论 辛伐他汀联合非诺贝特治疗高脂血症疗效可靠,安全性良好。     

小剂量阿托伐他汀钙联合非诺贝特治疗混合型高脂血症合并高尿酸血症的临床观察

目的 探讨小剂量的阿托伐他汀钙联合非诺贝特治疗高脂血症合并高尿酸血症的疗效及安全性。方法 选择我院2013年12月至2015年12月收治的混合型高脂血症伴高尿酸血症患者182例,按照随机数字法分为A组60例,B组61例和C组61例。A组患者给予阿托伐他汀钙10mg/次/d,口服;B组患者给予非诺贝特200mg/次/d,口服;C组患者给予阿托伐他汀钙10mg/次/d加非诺贝特200mg/次/d,口服。观察血清TC、LDL-C、TG、HDL-C和血尿酸(BUA)的变化及用药过程中的不良反应。结果 治疗8周后,3组患者各血脂指标均显著降低(P＜0.05)。B组和C组患者血清TG较A组下降更为显著,HDL-C升高更为显著(P＜0.05)。A组和C组患者血清TC和LDL-C较B组下降更为显著(P＜0.05)。B组和C组患者BUA水平显著降低(P＜0.05)。治疗后B组和C组患者BUA水平显著低于A组(P＜0.05)。3组患者不良反应的发生率无显著差异(P＞0.05)。结论 小剂量的阿托伐他汀钙联合非诺贝特能有效降低高脂血症合并高尿酸血症患者血清TG、TC、HDL-C和BUA的水平,同时升高HDL-C的水平,且不良反应发生率低,安全性高。     

氟伐他汀联合非诺贝特治疗混合性高脂血症的可行性探讨

目的观察氟伐他汀联合非诺贝特治疗混合性高脂血症的临床效果。方法选择2007年1月至2008年12月南通市老年康复医院心内科门诊混合性高脂血症患者180例,随机分为氟伐他汀组、非诺贝特组、联合用药组各60例;氟伐他汀组每晚口服40mg氟伐他汀、非诺贝特组每晚口服非诺贝特200mg、联合用药每日清晨口服非诺贝特200mg,晚口服氟伐他汀20mg,均用至12周。观察血脂参数变化、疗效评价、药物主要不良反应。结果三组TC、LDL-C、TG治疗前无差异(P>0.05),氟伐他汀组治疗后TC、LDL-C均有显著性下降(P<0.05),TG变化不明显(P>0.05);非诺贝特组治疗后TG有显著性下降(P<0.05),TC、LDL-C变化不明显(P>0.05);联合用药组TC、LDL-C、TG均有显著性下降(P<0.05)。联合用药组临床控制(显效、好转)83.3%(50/60)高于氟伐他汀组的68.3%(41/60)和非诺贝特组的65.0%。三组患者血清CK、肝肾功能等参数均无明显变化,未出现肌病症状,无1例退出或终止。结论氟伐他汀联合非诺贝特对混合性高脂血症具有良好的安全性与耐受性,具有临床应用可行性。     

小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症临床疗效及安全性

目的:观察小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症临床疗效及安全性。方法:142例混合型高血脂患者随机分成A、B两组,两组均给予普伐他汀和非诺贝特联合治疗,A组普伐他汀用量为20mg,B组为10mg,连续用药3个月。检查两组患者治疗前后血脂水平变化,根据血脂水平变化将治疗效果分为痊愈、有效、无效和恶化4个等级,统计治疗总有效率和不良反应发生率。结果:两组患者治疗后TC、TG、LDL-C水平有明显下降,而HDL-C水平有明显升高(P0.05),但B组数据优于A组(P0.05);B组治疗总有效率(85.71%)高于A组(72.31%),但不存在统计学差异(P0.05);B组不良反应发生率(14.28%)低于A组(52.31%),差异有统计学意义(P0.05)。结论:小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症具有较好的临床效果,且安全性较高,可以在临床推广应用。     

辛伐他汀和微粒化非诺贝特对混合型高脂血症的疗效比较 (附56例分析)

目的比较辛伐他汀和微粒化非诺贝特对混合型高脂血症的疗效.方法56例混合型高脂血症患者随机分为两组,一组接受辛伐他汀(20mg qn,n=28)治疗,一组接受微粒化非诺贝特(200mg qd,n=28)治疗,疗程6周,观察治疗前后血脂成份的变化.结果两组治疗后均能明显降低总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C),升高高密度脂蛋白胆固醇(HDL-C),但辛伐他汀降低TC、LDL-C、LDL-C/HDL-C的幅度比微粒化非诺贝特高(P＜0.05),而微粒化非诺贝特降低TG的幅度比辛伐他汀大(P＜0.05),辛伐他汀治疗后TC、LDL-C恢复至正常水平的百分比显著比微粒化非诺贝特高(P＜0.05),而TG降至正常水平的百分比,微粒化非诺贝特比辛伐他汀高(P＜0.05).结论本研究提示对于甘油三脂轻至中度升高的混合型高脂血症患者,他汀类调脂药为首选药物;而对于严重的高甘油三脂血症者,非诺贝特则是合适的选择.大剂量辛伐他汀(20mg)与微粒化非诺贝特(200mg)均有报告认为能全面调脂[1],但两种药作用机制不同,调脂侧重点不同,如何选择是临床医生面临的困境.本研究旨在比较大剂量辛伐他汀及微粒化非诺贝特对混合型高脂血症的疗效,指导临床用药.     

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

OBJECTIVE: The aim of this study was to evaluate the amount of low-density lipoprotein cholesterol (LDL-C) reduction achieved by adding the specifically engineered bile acid sequestrant (SE-BAS) colesevelam HCl to a stable dose of fenofibrate in patients with mixed hyperlipidemia. RESEARCH DESIGN AND METHODS: Patients with mixed hyperlipidemia (n = 129) were enrolled in a randomized, double-blind, placebo-controlled, parallel-group study investigating the efficacy of fenofibrate plus colesevelam HCl versus fenofibrate monotherapy. After a 4- to 8-week washout period, subjects received fenofibrate 160 mg/day for 8 weeks and were then randomized to receive colesevelam HCl 3.75 g/day or placebo, in addition to fenofibrate 160 mg/day, for 6 weeks. MAIN OUTCOMES MEASURES: The primary efficacy endpoint was mean percent change in LDL-C during randomized treatment. Secondary endpoints included absolute and percent changes in mean levels of LDL-C, triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol (TC), and apolipoproteins (apo) A-I and B during randomized treatment and from washout to end of randomized treatment. RESULTS: Of the 129 patients randomized to treatment, 119 completed the study. After 6 weeks of treatment, fenofibrate plus colesevelam HCl produced a mean percent change in LDL-C of -10.4% versus +2.3% with fenofibrate monotherapy (p < 0.0001). Fenofibrate plus colesevelam HCl was significantly more effective than fenofibrate alone at reducing levels of non-HDL-C, TC, and apo B (p < or = 0.0002). Colesevelam HCl did not significantly affect the TG-lowering effects of fenofibrate. Both treatment regimens were safe and well tolerated. CONCLUSIONS: Compared with fenofibrate monotherapy in patients with mixed hyperlipidemia, fenofibrate/colesevelam HCl combination therapy significantly reduced mean LDL-C, non-HDL-C, TC, and apo B levels without significantly affecting the TG-lowering or HDL-C-raising effects of fenofibrate. Fenofibrate/colesevelam HCl combination therapy is a safe, useful alternative for the treatment of mixed hyperlipidemia.     

Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy

Abstract

Objective:

To assess the long-term safety and efficacy of a fenofibrate/pravastatin 160/40?mg fixed-dose combination in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40?mg monotherapy.     

Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia

Micronized fenofibrate lowers total cholesterol and low-density lipoprotein cholesterol to a similar extent as statins but raises high-density lipoprotein cholesterol and lowers triglycerides to a greater extent. The comparative lipid-modifying efficacy of micronized fenofibrate and pravastatin has not been evaluated in dyslipidemic patients. This prospective, multicenter, randomized trial compared the efficacy of 3 months' treatment with micronized fenofibrate (200 mg once daily) or pravastatin (20 mg once daily) in hypercholesterolemic type IIa and mixed dyslipidemic type IIb patients. Two hundred sixty-five male and female patients (18-75 years) were recruited from 28 European centers, and 151 were analyzed. Micronized fenofibrate was at least as effective as pravastatin in reducing levels of low-density lipoprotein cholesterol and total cholesterol in primary dyslipidemia but was significantly more effective than pravastatin in raising high-density lipoprotein cholesterol (respectively, 13.2% vs. 5.6%; p = 0.0084) and lowering triglycerides (-38.7% vs. -11.8%; p = 0.0001). In type IIa dyslipidemia, micronized fenofibrate was as effective as pravastatin in raising high-density lipoprotein cholesterol (+8.6% vs. +8.0%) but was fivefold more effective in lowering triglycerides (-34.3% vs. -7.2%; p = 0.0001). In type IIb dyslipidemic patients with low baseline high-density lipoprotein cholesterol levels, micronized fenofibrate was 10-fold and nearly 3-fold superior to pravastatin in raising high-density lipoprotein cholesterol and lowering triglycerides, respectively. Micronized fenofibrate may be considered an effective first-line therapy for patients with primary hyperlipidemia, particularly those with type IIb mixed dyslipidemia or type 2 diabetes.     

Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia

Micronised fenofibrate is a synthetic phenoxy-isobutyric acid derivative (fibric acid derivative) indicated for the treatment of dyslipidaemia. Recently, a new tablet formulation of micronised fenofibrate has become available with greater bioavailability than the older capsule formulation. The micronised fenofibrate 160mg tablet is bioequivalent to the 200mg capsule. The lipid-modifying profile of micronised fenofibrate 160mg (tablet) or 200mg (capsule) once daily is characterised by a decrease in low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels, a marked reduction in plasma triglyceride (TG) levels and an increase in high-density lipoprotein cholesterol (HDL-C) levels. Micronised fenofibrate 200mg (capsule) once daily produced greater improvements in TG and, generally, in HDL-C levels than the hydroxymethylglutaryl coenzyme A reductase inhibitors simvastatin 10 or 20 mg/day, pravastatin 20 mg/day or atorvastatin 10 or 40 mg/day. Combination therapy with micronised fenofibrate 200mg (capsule) once daily plus fluvastatin 20 or 40 mg/day or atorvastatin 40 mg/day was associated with greater reductions from baseline than micronised fenofibrate alone in TC and LDL-C levels. Similar or greater changes in HDL-C and TG levels were seen in combination therapy, compared with monotherapy, recipients. Micronised fenofibrate 200mg (capsule) once daily was associated with significantly greater improvements from baseline in TC, LDL-C, HDL-C and TG levels than placebo in patients with type 2 diabetes mellitus enrolled in the double-blind, randomised Diabetes Atherosclerosis Intervention Study (DAIS) [> or =3 years follow-up]. Moreover, angiography showed micronised fenofibrate was associated with significantly less progression of coronary atherosclerosis than placebo. Micronised fenofibrate has also shown efficacy in patients with metabolic syndrome, patients with HIV infection and protease inhibitor-induced hypertriglyceridaemia and patients with dyslipidaemia secondary to heart transplantation. Micronised fenofibrate was generally well tolerated in clinical trials. The results of a large (n = 9884) 12-week study indicated that gastrointestinal disorders are the most frequent adverse events associated with micronised fenofibrate therapy. Elevations in serum transaminase and creatine phosphokinase levels have been reported rarely with micronised fenofibrate. In conclusion, micronised fenofibrate improves lipid levels in patients with primary dyslipidaemia; the drug has particular efficacy with regards to reducing TG levels and raising HDL-C levels. Micronised fenofibrate is also effective in diabetic dyslipidaemia; as well as improving lipid levels, the drug reduced progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. The results of large ongoing studies (e.g. FIELD with approximately 10 000 patients) will clarify whether the beneficial lipid-modifying effects of micronised fenofibrate result in a reduction in cardiovascular morbidity and mortality.     

Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia

Mixed hyperlipidemia is a major cause of coronary artery disease. Monotherapy with statins is considered the gold standard for treatment of mixed hyperlipidemia. But greater benefit may be expected by combination therapy. Combination may allow lower doses of statins and less adverse effects. Hence, this preliminary study was designed to evaluate the efficacy and safety of low-dose atorvastatin in combination with fenofibrate in patients with mixed hyperlipidemia. Ninety patients were assigned into three groups and received atorvastatin (10-40 mg/day) or fenofibrate (160-200 mg/day) or combination of low-dose atorvastatin (5 mg/day) and fenofibrate (160 mg/day). There was a significant decrease in low-density lipoprotein (LDL), triglycerides (TG) and total cholesterol (TC), and a significant increase in high-density lipoprotein (HDL) in all the groups at the end of therapy. Combination therapy produced maximum decrease in LDL, TG and TC, and maximum increase in HDL when compared with monotherapies. No significant difference was reported in safety profile between the two groups. To conclude, the results suggest that combination therapy with low-dose atorvastatin and fenofibrate is more efficacious, with no increase in adverse effects when compared with monotherapies with individual drugs for mixed hyperlipidemia. The results are preliminary and suggestive only, as the study was open and nonrandomized.     

Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme

BACKGROUND and objective: Atherogenic lipid parameters in patients with mixed dyslipidaemia have been demonstrated to increase atherosclerotic coronary heart disease (CHD) risk. Clinical studies have shown that HMG-CoA reductase inhibitor (statin) and fibric acid derivative (fibrate) combination therapy is effective at improving multiple lipid abnormalities in different patient populations at increased risk of CHD. However, inconsistencies with respect to trial designs and safety issues have limited the clinical use of this combination therapy. A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new formulation of fenofibric acid. METHODS: Three separate 22-week, phase III, double-blind, active-controlled trials will evaluate combination therapy with ABT-335 135 mg/day and either rosuvastatin (10 mg/day and 20 mg/day), atorvastatin (20 mg/day and 40 mg/day) or simvastatin (20 mg/day and 40 mg/day) in comparison to either ABT-335 or the corresponding statin monotherapy. An approximate total of 2400 patients with elevated triglycerides (TG) [> or =150 mg/dL], reduced high-density lipoprotein cholesterol (HDL-C) [<40 mg/dL for men and <50 mg/dL for women], and elevated low-density lipoprotein cholesterol (LDL-C) [> or =130 mg/dL] will be randomized to one of six intervention arms per trial (two combination therapy and four monotherapy groups). The pre-specified primary efficacy endpoint is a composite of the mean percent changes in HDL-C and TG (comparing each combination therapy with the corresponding statin monotherapy dose) and LDL-C (comparing each combination therapy with ABT-335 monotherapy). Secondary endpoints include mean percent changes in non-HDL-C, very LDL-C, total cholesterol, apolipoprotein B and high sensitivity C-reactive protein levels. At study end, patients may enroll in a 12-month open-label extension study that will evaluate the long-term efficacy and safety of combination therapy. CONCLUSION: This is the largest phase III randomized, controlled clinical programme to date evaluating the efficacy and safety of the combined use of a new formulation of fenofibric acid (ABT-335) with three commonly prescribed statins in patients with mixed dyslipidaemia.     

氟伐他汀与普伐他汀治疗高脂血症疗效比较

目的 :观察并比较氟伐他汀与普伐他汀的降脂疗效。方法 :氟伐他汀组 4 1例 (男性 2 2例 ,女性 19例 ,年龄 6 0a±s 8a) ,应用氟伐他汀 2 0～ 4 0mg ,po ,qn× 4wk。普伐他汀组 35例 (男性 2 0例 ,女性 15例 ,年龄 6 0a± 6a) ,应用普伐他汀 10mg ,po ,qn× 4wk。结果 :氟伐他汀降低TC的总有效率 92 % ,普伐他汀为 70 % (P <0 .0 5) ;氟伐他汀降低TG及升高HDL C的总有效率为 6 1%和 6 1% ,与普伐他汀的 73%和 6 9%相似 (P >0 .0 5)。 2组的不良反应发生率为 2 0 % (8/41)和 2 0 % (7/35)。结论 :氟伐他汀是一种安全、有效的降脂药物 ,且降低TC作用优于普伐他汀。     

Effect of rimonabant,micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study

Objective: To assess the effect of rimonabant, micronised fenofibrate and their combination on anthropometric and metabolic parameters in overweight/obese patients with dyslipidaemia. Methods: All patients (n = 30) received a hypocaloric diet (～ 600 kcal/day deficit) and were randomly allocated to receive open-label rimonabant (R) 20 mg/day (n = 10), micronised fenofibrate (F) 200 mg/day (n = 10) or rimonabant 20 mg/day plus fenofibrate 200 mg/day (RF) (n = 10). Anthropometric and metabolic parameters were assessed at baseline and 3 months after treatment initiation. Results: Compared with baseline similar significant reductions in body weight, body mass index and waist circumference were observed in the R (–6, –5 and –5%, respectively; p < 0.01) and RF group (–5% for all, p < 0.05), while improvements in these parameters were smaller in the F group (–2, –2.5 and –2%, respectively; p < 0.05). Triglycerides were reduced by 18% in the R group (p = NS), by 39% in the F group (p < 0.001) and by 46% in the RF group (p < 0.05). Importantly, combination treatment resulted in a 42% increase in high-density lipoprotein cholesterol (HDL-C) levels (p < 0.05), while HDL-C was not significantly altered in the two monotherapy groups. Subsequently, a more pronounced increase in apolipoprotein A-I (ApoA-I) levels (+25%) was observed in the RF group compared with changes in both monotherapy groups (p < 0.0001 vs R and p < 0.005 vs F group). Low-density lipoprotein cholesterol (LDL-C) levels were not significantly altered in any group. Apolipoprotein B (apoB) levels were reduced in all groups and this reduction was significantly more pronounced in the RF group (p < 0.05 vs baseline as well as p < 0.005 and p < 0.01 for RF vs R and F groups, respectively). ApoB/apoA-I ratio decreased by 3% with R (p = NS), by 18% with F (p < 0.05) and by 40% with RF treatment (p < 0.01). Total cholesterol to HDL-C ratio decreased by 20% with F (p < 0.0001) and by 33% with RF therapy (p < 0.005), while it was not significantly altered in R group. Conclusion: The combination of rimonabant and fenofibrate may further improve metabolic parameters in overweight/obese patients with dyslipidaemia compared with each monotherapy. This improvement is particularly pronounced for HDL-C levels.